Human Epididymis Protein 4: A Novel Biomarker for Lupus Nephritis and Chronic Kidney Disease in Systemic Lupus Erythematosus

Overview

Journal J Clin Lab Anal

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
Pathology

Date 2016 Apr 15

PMID 27075413

Citations 11

Authors

Zaixing Yang

Zhiyu Zhang

Baodong Qin

Ping Wu

Renqian Zhong

Lin Zhou

Yan Liang

Affiliations

Soon will be listed here.

Abstract

Background: Human epididymis protein 4 (HE4) is an available tumor biomarker for detecting ovarian cancer. However, it is unknown if serum HE4 could be a novel biomarker for diagnosis of lupus nephritis (LN) and chronic kidney disease (CKD) in patients with systemic lupus erythematosus (SLE).

Methods: This study enrolled 209 SLE patients, 75 patients with renal dysfunction without SLE and 32 healthy subjects. HE4 concentrations were analyzed by ELISA (enzyme-linked immunosorbent assay; Fujirebio Diagnostics, Sweden). The receiver operating characteristic (ROC) curves were constructed to assess diagnostic accuracy of HE4 for LN or CKD in SLE.

Results: Serum HE4 level was significantly higher in SLE patients than that in healthy controls (P < 0.001), especially for those with LN or CKD. It was also higher in patients with renal dysfunction without SLE than healthy controls (P < 0.001), while there was no significant difference between these patients and those with SLE with CKD (P = 0.73). Multivariate analysis showed significant association between increased HE4 and LN or CKD after controlling for confounders. ROC curves showed the cutoff values were 150.1 pM (sensitivity, 76.8%; specificity, 91.1%) for the diagnosis of LN in SLE and 233.9 pM (sensitivity, 92.9%; specificity, 93.5%) for CKD in SLE.

Conclusions: Increased serum HE4 level is closely associated with the development of LN or CKD in SLE patients. Furthermore, it can be used as a novel and useful biomarker for diagnosis of LN or CKD.

Citing Articles

Increased serum human epididymis protein 4 is associated with disease activity and systemic involvement in pediatric-onset systemic lupus erythematosus.

Liu C, Yan L, Zhang M, Duan Y, Luo J, Liu Z Front Immunol. 2024; 15:1461987.

PMID: 39318632 PMC: 11419971. DOI: 10.3389/fimmu.2024.1461987.

Lupus Nephritis Biomarkers: A Critical Review.

Alduraibi F, Tsokos G Int J Mol Sci. 2024; 25(2).

PMID: 38255879 PMC: 10815779. DOI: 10.3390/ijms25020805.

Silencing HE4 alleviates the renal fibrosis in lupus nephritis mice by regulating the C3/MMPs/prss axis.

Li Y, Zhong X, Yang F Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(7):4823-4831.

PMID: 38157023 PMC: 11166803. DOI: 10.1007/s00210-023-02883-x.

Elevated serum levels of human epididymis protein 4 in adult patients with proliferative lupus nephritis.

Li L, Xu H, Le Y, Li R, Shi Q, Zhu H Front Immunol. 2023; 14:1179986.

PMID: 37287983 PMC: 10243370. DOI: 10.3389/fimmu.2023.1179986.

Current Insights on Biomarkers in Lupus Nephritis: A Systematic Review of the Literature.

Palazzo L, Lindblom J, Mohan C, Parodis I J Clin Med. 2022; 11(19).

PMID: 36233628 PMC: 9570701. DOI: 10.3390/jcm11195759.

References

Sun H, Hu W, Xie H, Zhang H, Chen H, Zeng C . Long-term outcome of Chinese patients with membranous lupus nephropathy. Lupus. 2007; 17(1):56-61. DOI: 10.1177/0961203307083443. View

Bingle C, Vyakarnam A . Novel innate immune functions of the whey acidic protein family. Trends Immunol. 2008; 29(9):444-53. DOI: 10.1016/j.it.2008.07.001. View

Siso A, Ramos-Casals M, Bove A, Brito-Zeron P, Soria N, Nardi N . Outcomes in biopsy-proven lupus nephritis: evaluation of 190 white patients from a single center. Medicine (Baltimore). 2010; 89(5):300-307. DOI: 10.1097/MD.0b013e3181f27e8f. View

Reich H, Gladman D, Urowitz M, Bargman J, Hladunewich M, Lou W . Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus. Kidney Int. 2011; 79(8):914-20. DOI: 10.1038/ki.2010.525. View

Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H . Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer. 2009; 100(8):1315-9. PMC: 2676558. DOI: 10.1038/sj.bjc.6605011. View

Faurschou M, Starklint H, Halberg P, Jacobsen S . Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheumatol. 2006; 33(8):1563-9. View

Levey A, Eckardt K, Tsukamoto Y, Levin A, Coresh J, Rossert J . Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005; 67(6):2089-100. DOI: 10.1111/j.1523-1755.2005.00365.x. View

. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum. 2006; 54(2):421-32. DOI: 10.1002/art.21625. View

Andersen M, Goff B, Lowe K, Scholler N, Bergan L, Drescher C . Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol. 2009; 116(3):378-83. PMC: 2822097. DOI: 10.1016/j.ygyno.2009.10.087. View

10.

Bingle L, Cross S, High A, Wallace W, Rassl D, Yuan G . WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Respir Res. 2006; 7:61. PMC: 1459147. DOI: 10.1186/1465-9921-7-61. View

11.

Nagy Jr B, Krasznai Z, Balla H, Csoban M, Antal-Szalmas P, Hernadi Z . Elevated human epididymis protein 4 concentrations in chronic kidney disease. Ann Clin Biochem. 2012; 49(Pt 4):377-80. DOI: 10.1258/acb.2011.011258. View

12.

Korbet S, Lewis E, Schwartz M, Reichlin M, Evans J, Rohde R . Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis. 2000; 35(5):904-14. DOI: 10.1016/s0272-6386(00)70262-9. View

13.

Nagy G, Brozik M, Varga L, Fust G, Kirschfink M, Kiss E . Usefulness of detection of complement activation products in evaluating SLE activity. Lupus. 2000; 9(1):19-25. DOI: 10.1177/096120330000900105. View

14.

Bombardier C, Gladman D, Urowitz M, Caron D, Chang C . Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992; 35(6):630-40. DOI: 10.1002/art.1780350606. View

15.

Romeo V, Framarino Dei Malatesta M, Nudo F, Simonelli L, Derme M, Berloco P . Is HE4 serum level a valid screening test in women candidates for kidney transplant? A case report and a review of literature. Clin Ter. 2014; 165(2):e162-5. DOI: 10.7471/CT.2014.1702. View

16.

Nolen B, Velikokhatnaya L, Marrangoni A, De Geest K, Lomakin A, Bast Jr R . Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol. 2010; 117(3):440-5. PMC: 2873171. DOI: 10.1016/j.ygyno.2010.02.005. View

17.

Illei G, Tackey E, Lapteva L, Lipsky P . Biomarkers in systemic lupus erythematosus: II. Markers of disease activity. Arthritis Rheum. 2004; 50(7):2048-65. DOI: 10.1002/art.20345. View

18.

Chawla L, Eggers P, Star R, Kimmel P . Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med. 2014; 371(1):58-66. PMC: 9720902. DOI: 10.1056/NEJMra1214243. View

19.

Bingle L, Singleton V, Bingle C . The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene. 2002; 21(17):2768-73. DOI: 10.1038/sj.onc.1205363. View

20.

Esdaile J, Joseph L, Mackenzie T, Kashgarian M, HAYSLETT J . The benefit of early treatment with immunosuppressive agents in lupus nephritis. J Rheumatol. 1994; 21(11):2046-51. View